Clinical Trial Update: Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan [Phase 2]

View source ↗

Summary

A randomized Phase 2 study evaluating ALECSAT in glioblastoma multiforme compared to Avastin/irinotecan has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• ALECSAT
• Avastin (bevacizumab)
• Camptosar (irinotecan)

Snippet

Sponsor: CytoVac A/S | Conditions: Glioblastoma Multiforme | Phase 2 | Status: TERMINATED